Raymond James Financial Inc. lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 4,144.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 509,379 shares of the company's stock after acquiring an additional 497,379 shares during the period. Raymond James Financial Inc. owned approximately 0.51% of Trevi Therapeutics worth $3,204,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Two Sigma Investments LP bought a new stake in shares of Trevi Therapeutics during the 4th quarter worth approximately $560,000. Ameriprise Financial Inc. raised its stake in Trevi Therapeutics by 187.0% during the fourth quarter. Ameriprise Financial Inc. now owns 96,784 shares of the company's stock worth $399,000 after acquiring an additional 63,067 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in Trevi Therapeutics during the first quarter worth about $197,000. Northern Trust Corp raised its stake in Trevi Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 482,815 shares of the company's stock worth $1,989,000 after acquiring an additional 49,173 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Trevi Therapeutics by 774.9% in the fourth quarter. Millennium Management LLC now owns 180,419 shares of the company's stock valued at $743,000 after buying an additional 159,798 shares during the period. Institutional investors own 95.76% of the company's stock.
Trevi Therapeutics Price Performance
Trevi Therapeutics stock traded up $0.14 during trading hours on Thursday, reaching $9.76. The company had a trading volume of 4,150,417 shares, compared to its average volume of 1,941,020. The company has a 50-day moving average price of $7.24 and a 200 day moving average price of $6.45. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -23.26 and a beta of 0.71. Trevi Therapeutics, Inc. has a 12-month low of $2.36 and a 12-month high of $9.92.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. As a group, research analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.
Wall Street Analysts Forecast Growth
TRVI has been the subject of several recent research reports. Morgan Stanley initiated coverage on Trevi Therapeutics in a research note on Thursday, August 21st. They issued an "overweight" rating and a $18.00 price objective for the company. Needham & Company LLC decreased their target price on Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Cantor Fitzgerald began coverage on Trevi Therapeutics in a research report on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price target for the company. Finally, Wall Street Zen downgraded Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $21.75.
Check Out Our Latest Analysis on Trevi Therapeutics
Trevi Therapeutics Company Profile
(
Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Recommended Stories
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
